Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26972830 | 0.90 | ABCC1 (0.52) | KCNMA1KMT2AMEN1MAPTABCB1 | |
| SCHEMBL6433978 | 0.89 | RXFP1 (0.54) | KCNMA1NPC1RAB9AMAPTNPSR1 | |
| SCHEMBL8231247 | 0.87 | ALDH1A1 (0.58) | KCNMA1KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL31365089 | 0.87 | ALDH1A1 (0.58) | KCNMA1KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL15160073 | 0.86 | HTT (0.53) | KMT2AALDH1A1NPC1RAB9AMAPK1 | |
| SCHEMBL5557413 | 0.85 | NPC1 (0.48) | KCNMA1KMT2AMEN1ALDH1A1NPC1 | |
| SCHEMBL29799606 | 0.85 | KCNMA1 (0.53) | KCNMA1KMT2AMEN1ALDH1A1NPC1 | |
| SCHEMBL29430688 | 0.85 | ABCB1 (0.53) | KMT2AMEN1ALDH1A1NPC1RAB9A | |
| SCHEMBL975856 | 0.85 | ABCB1 (0.53) | KMT2AMEN1ALDH1A1NPC1RAB9A | |
| SCHEMBL14740824 | 0.85 | KMT2A (0.45) | KCNMA1KMT2AMEN1ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113795256-B | FGFR inhibitors for treatment of cancer | 布里奇恩生物科学公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-113795256-A | FGFR inhibitors for the treatment of cancer | 布里奇恩生物科学公司 | 2021-12-14 | — | — | CN | disclosed |
| US-20080090816-A1 | ANTI-INFECTIVE BIARYL COMPOUNDS | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-7265129-B2 | Anti-infective biaryl compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| EP-0912175-A4 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1999-09-08 | — | — | EP | disclosed |
| EP-0912175-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1999-05-06 | — | — | EP | disclosed |
| US-5854245-A | Fibrinogen receptor antagonists | MERCK & CO., INC. (US) | 1998-12-29 | — | — | US | disclosed |
| WO-1998000134-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1998-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090816-A1 | ANTI-INFECTIVE BIARYL COMPOUNDS | QTRT1, Q6ZSR9, QTRT2 | KCNMA1 4587/4885KMT2A 3292/4885MEN1 4449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.